Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 653 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Total Cholesterol Clear all

Conditions: Dyslipidemia
Interventions: Lapaquistat Acetate, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 47
States / cities: Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more

Conditions: COVID-19, COVID-19 Immunisation
Interventions: mRNA-1273, mRNA-1273.351; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Decatur, Georgia • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: Hypercholesterolemia
Interventions: bempedoic acid 180mg, placebo, evolocumab; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
Interventions: Placebo, Citicoline, Pregnenolone; Drug · Dietary Supplement
Lead sponsor: Sherwood Brown, MD, PhD; Other
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 3
States / cities: Miami, Florida • Dallas, Texas • Edinburg, Texas

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: NIRS-IVUS Imaging (TVC Imaging System); Device
Lead sponsor: Infraredx; Industry
Eligibility: Not listed
Enrollment: 1,563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 31
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlantis, Florida + 25 more

Conditions: Inflammation
Interventions: vegetarian burger, beef burger; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 21 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Cerebrotendinous Xanthomatosis
Interventions: chenodeoxycholic acid, lovastatin; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Intermittent Fasting
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 21 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Conditions: HIV Infections, AIDS, Dyslipidemia, Hypertriglyceridemia
Interventions: Omega-3 fatty acid administration, Placebo; Drug
Lead sponsor: Brown, Todd, M.D., Ph.D.; Individual
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: LDL Cholesterol
Interventions: LIB003; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 5
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio

Conditions: Hyperlipidemia
Interventions: Atorvastatin, Placebo to Atorvastatin, Placebo to Ezetimibe, Ezetimibe, Placebo to Evolocumab, Evolocumab; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 18
States / cities: Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more

Conditions: Genital Herpes Simplex Type 2
Interventions: GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo; Biological
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 20 more

Conditions: Hyperlipidemia
Interventions: ETC-1002, Atorvastatin, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 19
States / cities: Anaheim, California • Los Angeles, California • Northridge, California + 16 more

Conditions: Dyslipidemia
Interventions: LCP-AtorFen; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: High Cholesterol
Interventions: 5 mg rosuvastatin calcium with a Web App (combination product); Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 1,196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Systemic Lupus Erythematosus, Lupus
Interventions: pravastatin, aspirin, ramipril, Vitamins: B6, B12, and folate, heart health educational program; Drug · Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Genital Herpes, HSV-2 Infection
Interventions: GEN-003, Matrix-M2, 0.9% normal saline; Biological · Other
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: Not listed
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes, Cardiovascular Disease
Interventions: Process Incentive, Outcome Incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic), Sphingomyelin, C13 Stable isotope of Cholesterol; Dietary Supplement · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 40 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Type 1 Diabetes
Interventions: Evolocumab Cartridge, Atorvastatin Calcium Tablets, Ezetimibe Tablets, 18F-FDG, Angiocatheter 20IV, J-Wire, GlycoCheck Glycocalyx Measurement Software; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: New York, New York

Conditions: Hypercholesterolemia
Interventions: Fresh garlic or garlic supplements; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 30 Years to 65 Years
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

The Lipid-Rich Plaque Study

Beef Burger Versus a Vegetarian Burger

Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction

Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia

Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)

Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Process Versus Outcomes Incentives for Lipid Management

Intralumenal Effects on Cholesterol Absorption/Synthesis

Cholesterol Lowering and Residual Risk in Diabetes, Type 1

Comparing Effects of 3 Sources of Garlic on Cholesterol Levels